Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

June 24, 2018 7:17 pm

The Boehringer Ingelheim representative discusses how the future of empagliflozin research should shape out.

Category: News
About The Author
-
Previous

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Next

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Related Videos

Type-2-Diabetes-Dr-Hull-The-Focus-of-Treatment-in-T2D

Type 2 Diabetes: Dr Hull – The Focus of Treatment in T2D

Unleashing-the-Truth-Approaching-T2D-Treatment-as-a-Team-Sport

Unleashing the Truth: Approaching T2D Treatment as a Team Sport

Team-based-care-for-patients-with-T2D-and-kidney-disease-Katherine-R-Tuttle-Jay-H-Shubrook

Team-based care for patients with T2D and kidney disease | Katherine R Tuttle & Jay H Shubrook

4-simple-tips-to-reverse-Type-2-Diabetes

4 simple tips to reverse Type 2 Diabetes

Low-carb-for-diabetes-A-transformation-Diet-Doctor-Podcast

Low carb for diabetes: A transformation — Diet Doctor Podcast

Medication-adherence-in-Malaysian-patients-with-T2D-Video-abstract-81612

Medication adherence in Malaysian patients with T2D – Video abstract 81612